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Metabolic acidosisBisphosphonates are commonly prescribed for treatment of osteoporosis. Long-term use of bisphosphonates has
been correlated to atypical femoral fractures (AFFs). AFFs arise from fatigue damage to bone tissue that cannot be
repaired due to pharmacologic treatments. Despite fatigue being the primary damage mechanism of AFFs, the
effects of osteoporosis treatments on fatigue properties of cortical bone are unknown. To examine if fatigue-
life differences occur in bone tissue after different pharmacologic treatments for osteoporosis, we tested bone tis-
sue from the femurs of sheep given ametabolic acidosis diet to induce osteoporosis, followed by treatmentwith a
selective estrogen receptionmodulator (raloxifene), a bisphosphonate (alendronate or zoledronate), or parathy-
roid hormone (teriparatide, PTH). Beams of cortical bone tissue were created and tested in four-point bending
fatigue to failure. Tissue treated with alendronate had reduced fatigue life and less modulus loss at failure com-
pared with other treatments, while tissue treated with PTH had a prolonged fatigue life. No loss of fatigue life oc-
curred with zoledronate treatment despite its greater binding afﬁnity and potency compared with alendronate.
Tissue mineralization measured by microCT did not explain the differences seen in fatigue behavior. Increased
fatigue life with PTH suggests that current treatment methods for AFF could have beneﬁcial effects for restoring
fatigue life. These results indicate that fatigue life differs with each type of osteoporosis treatment.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Osteoporotic fractures are a substantial public health concern with
total fractures and associated costs estimated to continue to rise
through 2025 (Burge et al., 2007). Bisphosphonates are a commonly
prescribed class of anti-resorptive drug that increases bone mineral
density between 0 and 8% while reducing the risk of fracture by up to
50% in osteoporotic patients (Cummings et al., 2002; Liberman et al.,
1995). The large decrease in fracture risk despite the modest increase
in bone mineral density suggests a material property change inen: no disclosures.Anthony R.
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bisphosphonates has led to concern over inability to repair damaged
and older tissue (Allen and Burr, 2011). To fully understand the reduc-
tion in fracture risk, all fracture properties and mechanisms should be
examined.
Fracture of osteoporotic bone typically occurs through one of two
mechanisms, a single overload (traumatic failure), or repetitive sub-
fracture loads (fatigue failure; Fig. 1). Typical osteoporotic hip fractures
are due to a mechanical overload, in which the femoral head and neck
are subjected to loads that the bone cannot withstand due to reduced
bone mass. Fatigue loads are repetitive, sub-failure forces applied to
the tissue. Activities of daily living create fatigue loads that in turn create
microdamage in the tissue (Taylor et al., 2007). Healthy individuals
are unlikely to experience fatigue fractures under normal loading
conditions since damage to the bone is typically repaired before fracture
can occur. However, the tissue properties may be altered in individuals
using anti-resorptive treatments (Donnelly et al., 2012; Bala et al., 2012;
Paschalis et al., 2011; Roschger et al., 2008). Knowledge of fatigue on
bone tissue has been primarily gained from testing of machined sec-
tions of bones and has shown fatigue dependence with temperature,
stress amplitude, and bonemicrostructure (Pattin et al., 1996; Carter
Fig. 1. Comparison of monotonic and fatigue loading. In monotonic loaded samples, force is increased until the sample fails. In fatigue, a repetitive sub-failure load is applied creating
damage that eventually coalesces to cause failure.
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osteoporotic and treated tissue have focused on microdamage accu-
mulation rather than the material properties of the tissue (Allen and
Burr, 2011).
Bisphosphonates act through osteoclast inhibition, which leads to
reduced bone turnover, increased bonemass and increased mineraliza-
tion (Reszka and Rodan, 2003). However, injury within the tissue
cannot be remodeled leading to an accumulation of microdamage
(Mashiba et al., 2000, 2001; Yamagami et al., 2013; Allen and Burr,
2007). Reduced bone turnover with bisphosphonate treatment
increases mineralization and collagen maturity in bone tissue as mea-
sured by Fourier transform infrared spectroscopy (FTIR) (Gourion-
Arsiquaud et al., 2010). Tests on whole bones after bisphosphonate
therapy indicate an increase in monotonic strength and stiffness at
corticocancellous sites without concomitant changes to the tissue-
level modulus or ultimate strength (Allen and Burr, 2007, 2011). A
loss of toughness and energy dissipation in cortical and cancellous tissue
has been found with bisphosphonate treatment (Allen and Burr, 2011).
Fatigue properties are likely altered with bisphosphonate treatment;
however, minimal data regarding these properties have been published
(Allen and Burr, 2011). Increasedmicrodamage in both cortical and can-
cellous tissuewith bisphosphonate treatmentmay reﬂect an inability to
repair damage within the tissue (Mashiba et al., 2000, 2001; Yamagami
et al., 2013; Allen and Burr, 2007). Alendronate reduced the fatigue life
in beams created from rib bones from healthy canines; however, the
dosing was supraphysiological and osteoporosis was not induced prior
to treatment (Bajaj et al., 2014).
Long-term bisphosphonate use is associated with atypical femoral
fractures (AFFs) (Isaacs et al., 2010; Schilcher et al., 2011). AFF incidence
with bisphosphonate use is relatively low, but is associatedwith consid-
erablemorbidity (Lo et al., 2012). Themechanics of these fractures indi-
cate critical differences from typical osteoporotic fractures (Shane et al.,
2010, 2014). Association with low loads indicates that AFFs result from
repetitive (fatigue) loading rather than a single traumatic incident. The
transverse nature of the fractures suggests altered material properties
with the tissue becoming more brittle.Bisphosphonates are the most common therapy prescribed for oste-
oporosis treatment, but other treatments exist. Selective estrogen
receptor modulators (SERMs) reduce osteoporotic vertebral fracture
risk by 30–50% (Ettinger et al., 1999). SERMs bind to the estrogen recep-
tors with an afﬁnity similar to estradiol (Rey et al., 2009). Teriparatide
(PTH) has been beneﬁcial in patients who experience AFFs by inducing
increased bone remodeling, removal of older more fully mineralized
tissue and replacement with new less fully mineralized tissue (Chiang
et al., 2013). Mechanical property data for SERM and PTH treatments
of bone have focused on monotonic failure properties and have not
included fatigue.
The purpose of this study was to examine the fatigue and fracture
properties of bone tissue after different osteoporosis treatments using
a sheep model of osteopenia to determine if a correlation exists be-
tween fatigue life and treatment type. Osteopenia was induced in
sheep and followed by an osteoporosis treatment or vehicle. Beams of
known geometry created from the femoral diaphysis of these sheep
were loaded in four-point bending fatigue to failure. Given the inhibi-
tion of remodeling, and increased mineralization and collagen maturity
reported with bisphosphonate treatment, we theorized that a shorter
fatigue life will occur with bisphosphonate treatment.
2. Materials and methods
2.1. Animal model
(Table 1) samples used in this studywere from remaining femur tis-
sue from previously published and in progress studies (Burket et al.,
2013). For all studies we fed ametabolic acidosis (MA) diet to skeletally
mature sheep to induce osteopenia (MacLeay et al., 2004a). In the ﬁrst
study, sheep fed a normal diet served as healthy controls for the exper-
iment (C, n= 6). In the second study, sheepwere fed theMA diet for 12
months and given alendronate (ALN; n= 2), raloxifene (RAL; n= 2) or
a vehicle (MA1; n= 3) treatment duringmonths 7–12. The low sample
sizes were not planned and reﬂect factors beyond our control in the
experiment. To further examine bisphosphonate treatment, a third
Fig. 2. Set up for four-point bending fatigue loading. P = applied load. The span between
the inner supports was 5mm, and for the outer supports 20mm. A cyclic loadwas applied
to failure with strain levels between 400 and 4000 μstrain.
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followed by 6 months of treatment with zoledronate (Reclast, ZOL;
n = 6) or vehicle (MA2; n = 6) while continuing the MA diet. The
longer initial MA term in experiment threewas due to a delay in procur-
ing the zoledronate. In the second study, alendronate (0.15 mg/kg) and
raloxifene (0.8 mg/kg) were administered daily via a cannula placed
into the duodenum, whereas zoledronate (5 mg/sheep) was adminis-
tered as a single intravenous injection. This schedule replicates the
clinical dosing in which alendronate is taken orally daily or weekly
and zoledronate is administered intravenously once a year (Bone
et al., 2000; Black et al., 2007). All animal procedures were reviewed
and approved by the Colorado State University IACUC and the Hospital
for Special Surgery IACUC.
A fourth set of skeletally mature sheep were fed an MA diet for one
year after ovariectomy, which has been shown to induce osteopenia
(Macleay et al., 2004b). The sheep were then maintained on the
MA diet and were administered teriparatide (PTH, n = 6) or vehicle
(MA3 + OVX, n = 6) for one year. Treatment was administered daily
via subcutaneous injection (5 mcg/kg). All animal procedures were
reviewed and approved by the University of Minnesota IACUC and the
Hospital for Special Surgery IACUC.
2.2. Sample preparation
Sheepwere euthanized at the end of the speciﬁed treatment period.
Femurs were removed and stored at −20 °C in saline-soaked gauze
until the time of sample preparation. Beams were cut out of the medial
diaphysis of the femurs using a low speed diamond saw (Buehler
Isomet; Lake Bluff, IL, USA). Beams were then polished using 15, 5 and
1 μm lapping ﬁlms with ethylene glycol used as a lubricant to prevent
mineral leaching (Donnelly et al., 2006; Brock et al., 2013). The samples
were polished to a ﬁnal size of 2 × 2 × 25mm. After polishing, the sam-
ples were stored at−20 °C in hydroxyapatite-buffered saline-soaked
gauze until testing.
2.3. Fatigue testing
Beamswere tested in four-point bending fatigue (Boyce et al., 1998;
Diab and Vashishth, 2005) (Bose Electroforce LM-1, Eden Prairie,
Minnesota, USA). The bottom supports were placed 20 mm apart, and
the top loading points were placed 5 mm apart (Fig. 2). These positions
created a constant bending moment between the loading points and
limited the effects of crushing at the load points (Zhai et al., 1999).
Preconditioning was completed by 20 cycles of loading from 2 to 20 N.
These valueswere chosen through preliminary testing that demonstrat-
ed that these loads induced normal surface strains below the 2500 με
necessary to create microdamage and alter fatigue life (Pattin et al.,
1996). The initial ﬂexural modulus was measured from the 10th cycle
and calculated using the assumptions of linear elastic beam theory.
Initial modulus values were used to calculate the force necessary toTable 1
Samples usedwere from four different studies: [1] age-matched control sheep fed a normal die
diet and twelvemonths of MA diet and treated by vehicle (MA1), raloxifene (RAL) or alendrona
combined with vehicle (MA2) or zoledronate (ZOL); [4] sheep subjected to ovariectomy and f
parathyroid hormone (PTH). Control, MA1, RAL and ALN were euthanized after 12 months, MA
Month
n 1 2 3 4 5 6 7 8 9 10 11 1
Control 6 Normal diet
MA1 3 MA diet MA + vehicle
ALN 2 MA diet MA + alendronate
RAL 2 MA diet MA + raloxifene
MA2 6 MA diet MA + vehicle
ZOL 6 MA diet MA + zoledronate
MA3 + OVX 6 MA diet + OVX
PTH 6 MA diet + OVXachieve desired values of strain of 400 to 4000 με on the tensile and
compressive surfaces. The samples were loaded in force control from
400 to 4000 με (R = 0.1) to failure with peak-to-peak force and dis-
placement measured at each cycle. Cycles-to-failure, Nf, was deﬁned
as the number of cycles experienced before the sample broke. Modulus
loss at failure was deﬁned as the percent change in modulus from the
10th cycle to Nf, and was calculated with linear elastic beam theory
(Beer et al., 1996). All testingwas completed at physiologic temperature
(37 °C) in hydroxyapatite-buffered PBS (1 g HA added per 1 L PBS and
allowed to sit overnight until solution was supersaturated) with tem-
perature monitored continuously.
2.4. Microcomputed tomography (microCT)
Tissue mineral density (TMD) was measured with microCT at a
50 μm voxel size (eXplore CT 120, GE Healthcare, Waukesha, WI,
USA). A mineral phantom was used for calibration with analysis
completed in Microview (version ABA 2.2, GE Healthcare, Waukesha,
WI, USA).
2.5. Statistical analysis
The purpose of the experiment was to determine differences in Nf
among the different treatment groups and correlate the differences to
TMD data. A standard least squares analysis was used to compare each
group to the grand mean of the data. The four separate experimentst (control); [2] sheep fed ametabolic acidosis (MA) diet for sixmonths followed by theMA
te (ALN); [3] sheep fed anMA diet for eight months followed by sixmonths of theMA diet
ed an MA diet for a year, followed by a year of the MA diet and vehicle (MA3 + OVX) or
2 and ZOL at 14 months and MA3 + OVX and PTH at 24 months.
2 13 14 15 16 17 18 19 20 21 22 23 24
MA + OVX + vehicle
MA + OVX + PTH
Fig. 4. Cycles to failure for each group. Alendronate (ALN) had fewer cycles to failure
compared with the grand mean (p b 0.01). Teriparatide (PTH) had more cycles to failure
compared to the grand mean (p b 0.01). Markers to the left represent individual sample
data points. Box and whisker plots on the right show the minimum, maximum, mean,
and 25th and 75th quartiles. Dashed line represents the grand mean.
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was performed on the cycles-to-failure data to meet the assumption of
equal variance between groups.
Different treatments and durations of MA controls can inﬂuence the
results. Low sample sizes also limited comparisons among groups. For
comparison of the MA1, raloxifene and alendronate groups, a Student's
t-test was used to compare each group with a Bonferroni post hoc cor-
rection applied. A Student's t-test was completed also for the MA2 and
zoledronate data, MA3+ OVX data and PTH. The Bonferroni correction
and t-test comparisons were necessary due to low sample sizes and not
meeting the assumptions for an ANOVA.
3. Results
An increase in the initialﬂexuralmoduluswas seen in theMA3+OVX
and PTH groups as compared with the grand mean of all groups (Fig. 3).
The samples treated with alendronate had a signiﬁcantly lower Nf
compared with the grand mean of all groups (p b 0.01), while the PTH
samples had signiﬁcantly greater Nf compared with the grand mean
(p b 0.01; Fig. 4). A loss of fatigue life occurred between alendronate
(ALN) and its metabolic acidosis control (MA1; p b 0.01). Modulus loss
at failure was signiﬁcantly lower in the alendronate-treated group
compared with the grand mean (p b 0.05; Fig. 5).
Mineralization measures (TMD) did not account for the differences
in fatigue behavior. Control samples had a lower TMD compared with
the grand mean, while raloxifene raised the TMD above the grand
mean (p b 0.05; Fig. 6).
4. Discussion and conclusions
Fatigue properties were examined in cortical bone tissue from
sheep treated by anti-resorptive drugs after induction of osteoporosis.
Four-point bending fatigue testing to failure was completed at physio-
logic temperature on bone beams created from the femoral diaphysis.
Osteoporosis treatments had differing effects on the fatigue life of
cortical bone tissue. Alendronate treatment caused a signiﬁcant loss in
fatigue life as compared with the grand mean and its MA control; how-
ever, zoledronate-treated specimens did not experience any change
in fatigue life from the grand mean or MA control. Greater changes
might be expected with zoledronate than alendronate given
zoledronate's greater binding afﬁnity and potency (Russell et al.,
2008). Alendronate has a relative potency of 1–2 × 103, whereas
zoledronate has a relative potency of 104 compared with etidronate
(Shaw and Bishop, 2005). Raloxifene did not change the fatigue lifeFig. 3. Initial modulus values for each group. MA3 + OVX and PTH had higher initial
moduli than the other groups. Markers to the left represent individual sample data points.
Box and whisker plots on right show the minimum, maximum, mean, and 25th and 75th
quartiles for each group. Dashed line is the grand mean.of the tissue while PTH increased the fatigue life over the grand
mean of the data. Differences in the fatigue life indicate material prop-
erty changes caused by binding afﬁnity, dosing, chemical structure or
collagen changes.
Differences in the administration of the bisphosphonates may con-
tribute to the altered fatigue properties. Alendronate was administered
daily via cannula while zoledronate was given once over the course of
the experiment via intravenous injection following clinical dosing
regimens (Bone et al., 2000; Black et al., 2007). With daily dosing of
alendronate the bisphosphonate is present in the serum continuously
affecting biomarkers of bone turnover, whereas a single dose of
zoledronate may allow the serum biomarker levels to return to pre-
treatment homeostasis. Serum CTX is known to be reduced with bis-
phosphonate dosing and increase with time since last administration
(Rosen et al., 2000; Marx et al., 2007). Increased collagen maturity
occurs with bisphosphonate treatment, and suppression of serum
biomarkers such as CTX may indicate differences between the two
bisphosphonate types.
Bisphosphonate molecular structure and distribution throughout
the tissue are also theorized to have an effect on the tissue properties.
Regions of higher mineralization were surface-based on trabeculaeFig. 5.Modulus loss at failure for each group. Alendronate had a lower modulus loss at
failure compared with the grandmean (p b 0.05). Markers to the left represent individual
sample data points. Box and whisker plots on the right show the minimum, maximum,
mean, and 25th and 75th quartiles. Dashed line represents the grand mean.
Fig. 6. Mineralization measure for each group. Control samples had a lower TMD as
comparedwith the grandmeanwhile raloxifene samples had increased TMD as compared
with the grand mean (p b 0.05). Markers to the left represent individual sample data
points. Box and whisker plots on the right show the minimum, maximum, mean, and
25th and 75th quartiles. Dashed line represents the grand mean.
12 G.R. Brock et al. / Bone Reports 2 (2015) 8–13with zoledronate treatment (Burket et al., 2013), which supports the
idea that zoledronate has a more surface-based effect. The distribution
of bisphosphonates throughout cortical bone tissue has only been re-
ported with the use of ibandronate and differences in the distribu-
tion between proximal and distal cortices were noted (Smith et al.,
2003). Higher-afﬁnity bisphosphonates have less diffusion into bone,
which could cause differences between alendronate and zoledronate
(Nancollas et al., 2006).
Alendronate-treated samples had lowermodulus loss at failure indi-
cating amore brittlematerial. Microdamage quantities in these samples
were not analyzed, so differences in this parameter among groups are
unknown. Microdamage is associated with fatigue loading, and in-
creased microdamage is correlated to loss of modulus in trabecular
bone (Lambers et al., 2013). Greater microdamage created by activities
of daily living occurs in both cortical and cancellous tissues with
alendronate treatment compared with untreated control tissues
(Mashiba et al., 2000, 2001).
In this study, applied loads created maximum normal strains from
400 to 4000 με. In laboratory fatigue conditions in bending, damage
creation starts at 2500 με in regions under tension; however, greater
than 4000 με is necessary in the regions under compression (Pattin
et al., 1996). The 4000 με applied in our study would, therefore, create
damage in the tensile region with the compressive region receiving
little damage. Greater damage in the tensile region is similar to AFF
progression, in which the stress fracture develops from the lateral
cortex that is under tension during normal weight-bearing activities.
The results of this study are limited by several factors including the
underpowered sample sizes for both alendronate and raloxifene treat-
ments. As previously stated, small sample sizes were unplanned and
due to factors beyond our control in the experiment; however, recent
studies in a different animal model have also demonstrated a reduction
in fatigue life with alendronate treatment (Bajaj et al., 2014). The lack
of fatigue life change with raloxifene treatment may indicate fatigue
life preservation; however, this result may be due to a lack of power
from a small sample size. SERM therapies also have the side effect of
increased risk of thromboembolic problems (Gennari et al., 2007)
indicating that increased fatigue life alone may not make this therapy
more appropriate. Four-point bending fatigue is not a typical method
for fatigue measurements. Tensile and compressive fatigue are more
commonly used for material characterization (Pattin et al., 1996;
Carter and Hayes, 1976); however, limited tissue from repurposed
samples prevented the possibility of analyzing tissues by this method.
Finally, although having samples from four separate studies enhancedour ability to make comparisons, this situation was less than ideal as
sheep are known to experience seasonal differences in BMD (Arens
et al., 2007). Nevertheless, we did include untreated control samples
to compare with treatment group samples.
In this study fatigue life differences with osteoporosis treatments
depended on both the class of treatment, type of drug, and mode of
delivery. Alendronate caused a reduction in bone tissue fatigue life
while PTH caused an increase in fatigue life. Raloxifene and zoledronate
did not change fatigue life. Material property alterations may be due to
differences in chemical structure, mechanisms of actions of these drugs,
or dosing regimens by which the drugs are administered. Under the
conﬁnes of this study, drug uptake or the effect of dosing regimen
were not possible to examine; however, these variables are avenues
for future research that may help explain the occurrence of AFF.
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